Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-03-19 6:06 pm Sale | 2021-03-17 | 13D | ORIC Pharmaceuticals, Inc. ORIC | ORBIMED ADVISORS LLC | 2,467,292 6.800% | -298,425 (-10.79%) | Filing History |
| 2021-03-03 6:50 pm Sale | 2021-03-01 | 13D | SpringWorks Therapeutics, Inc. SWTX | ORBIMED ADVISORS LLC | 6,186,307 12.600% | -1,220,000 (-16.47%) | Filing History |
| 2021-03-01 6:13 pm Purchase | 2021-02-17 | 13D | Decibel Therapeutics, Inc. DBTX | ORBIMED ADVISORS LLC | 4,061,774 16.700% | 4,061,774 (New Position) | Filing History |
| 2021-03-01 6:09 pm Unchanged | 2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA | ORBIMED ADVISORS LLC | 188,568 8.410% | 0 (Unchanged) | Filing History |
| 2021-02-25 7:41 pm Sale | 2021-02-24 | 13D | Xtant Medical Holdings, Inc. XTNT | ORBIMED ADVISORS LLC | 72,803,072 93.600% | -7,309 (-0.01%) | Filing History |
| 2021-02-22 6:31 pm Purchase | 2021-02-09 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 3,791,204 15.100% | 3,791,204 (New Position) | Filing History |
| 2021-02-22 3:47 pm Purchase | 2021-02-05 | 13D | Gemini Therapeutics, Inc. GMTX | ORBIMED ADVISORS LLC | 582,622 12.900% | 582,622 (New Position) | Filing History |
| 2021-02-18 9:48 pm Purchase | 2021-02-12 | 13D | RESTORBIO INC TORC | ORBIMED ADVISORS LLC | 5,933,314 18.900% | 420,299 (+7.62%) | Filing History |
| 2021-02-17 5:08 pm Purchase | 2021-02-17 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 8,053,298 21.980% | 1,285,714 (+19.00%) | Filing History |
| 2021-02-12 5:13 pm Purchase | 2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | ORBIMED ADVISORS LLC | 1,711,305 4.890% | 1,076,493 (+169.58%) | Filing History |
| 2021-02-12 5:12 pm Purchase | 2020-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | ORBIMED ADVISORS LLC | 325,960 6.900% | 325,960 (New Position) | Filing History |
| 2021-02-12 5:10 pm Purchase | 2020-12-31 | 13G | Theravance Biopharma, Inc. TBPH | ORBIMED ADVISORS LLC | 5,544,212 8.670% | 5,544,212 (New Position) | Filing History |
| 2021-02-12 5:08 pm Purchase | 2020-12-31 | 13G | Strongbridge Biopharma plc SBBP | ORBIMED ADVISORS LLC | 2,986,869 4.440% | 2,986,869 (New Position) | Filing History |
| 2021-02-12 5:07 pm Sale | 2020-12-31 | 13G | Prothena Corporation plc PRTA | ORBIMED ADVISORS LLC | 1,485,458 3.720% | -802,981 (-35.09%) | Filing History |
| 2021-02-12 5:05 pm Purchase | 2020-12-31 | 13G | Otonomy, Inc. OTIC | ORBIMED ADVISORS LLC | 2,480,800 5.140% | 1,083,233 (+77.51%) | Filing History |
| 2021-02-12 5:04 pm Sale | 2020-12-31 | 13G | OBSEVA SA COM OBSVF | ORBIMED ADVISORS LLC | 0 0.000% | -2,605,531 (Position Closed) | Filing History |
| 2021-02-12 5:00 pm Purchase | 2020-12-31 | 13G | Mereo BioPharma Group plc MREO | ORBIMED ADVISORS LLC | 4,518,356 6.660% | 4,518,356 (New Position) | Filing History |
| 2021-02-12 4:59 pm Purchase | 2020-12-31 | 13G | MeiraGTx Holdings plc MGTX | ORBIMED ADVISORS LLC | 3,969,425 9.140% | 520,605 (+15.10%) | Filing History |
| 2021-02-12 4:57 pm Purchase | 2020-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | ORBIMED ADVISORS LLC | 732,323 4.770% | 732,323 (New Position) | Filing History |
| 2021-02-12 4:55 pm Sale | 2020-12-31 | 13G | Krystal Biotech, Inc. KRYS | ORBIMED ADVISORS LLC | 0 0.000% | -933,508 (Position Closed) | Filing History |